Cerevance Announces Presentation at AD/PD™ 2024 International Conference
February 27, 2024 08:30 ET
|
Cerevance
BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced plans to present a...
Cerevance to Participate at the TD Cowen 44th Annual Health Care Conference
February 22, 2024 08:30 ET
|
Cerevance
BOSTON, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced participation at the...
Cerevance Announces Publication of CVN766 in Bioorganic & Medicinal Chemistry Letters
February 15, 2024 08:30 ET
|
Cerevance
BOSTON, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced a publication describing...
Cerevance to Participate in Fireside Chat at the 2023 RBC Capital Markets Healthcare Private Company Virtual Conference
December 05, 2023 08:30 ET
|
Cerevance
BOSTON, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced that chief executive...
Cerevance Announces Presentation at the 34th International Symposium on ALS/MND
November 28, 2023 08:30 ET
|
Cerevance
BOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing novel precision therapeutics for central nervous system (CNS) diseases, today announced a poster presentation at...
Cerevance Doses First Patient in ASCEND Phase 2 Clinical Study of CVN424, a First-in-Class, Non-Dopaminergic Therapy for the Treatment of Parkinson’s Disease
November 13, 2023 08:30 ET
|
Cerevance
Study to assess efficacy and safety of CVN424 as a monotherapy in early-stage Parkinson’s disease BOSTON, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing novel...
Cerevance Announces Presentation at the SFN Neuroscience 2023 Annual Meeting
November 07, 2023 09:09 ET
|
Cerevance
BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing novel precision therapeutics for central nervous system (CNS) diseases, today announced plans to present a poster...
Cerevance to Participate in the Truist Securities BioPharma Symposium
November 01, 2023 08:00 ET
|
Cerevance
BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development developing precision novel therapeutics for central nervous system (CNS) diseases using...
Cerevance to Participate at the Wells Fargo 2023 Private Biotech Symposium
October 25, 2023 08:00 ET
|
Cerevance
BOSTON, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on developing precision novel therapeutics for central nervous system...
Cerevance to Participate at the Leerink Biopharma Private Company Connect
October 18, 2023 08:00 ET
|
Cerevance
BOSTON, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on developing precision novel therapeutics for central nervous system...